▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2305 by analyst upside · 2026-08-12
ASND
Ascendis Pharma A/S
Healthcare · Market Cap $17B · P/E 29.1x
ANALYST PRICE TARGET
+21.2%
implied upside to consensus target
Current Price $254.57
Consensus Target $308.53
Bull Target $358.16
Bear Target $260.64
Analysts Covering 18
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
14
Hold
0
Sell
0
52-Week Low $186.05
52-Week High $282.15
YTD Return +19.4%
FUNDAMENTALS
Market Cap $17B
P/E Ratio (TTM) 29.1x
Forward P/E 23.8x
EPS (TTM) $8.74
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $866M
Profit Margin 57.3%
52-WEEK RANGE
52-Week Low $186.05
52-Week High $282.15
Current Price $254.57
Bear Target $260.64
Bull Target $358.16
● Now $254.57 ● Target $308.53
TRADING DATA
Avg Volume 670K
YTD Return +19.4%
Analyst Count 18
Consensus Buy
Upside to Target +21.2%
Last Updated 2026-08-12

ANALYST SUMMARY

Ascendis Pharma A/S (ASND) is currently trading at $254.57 with a Wall Street consensus price target of $308.53, implying potential upside of 21.2% over the next 12 months. 18 analysts currently cover ASND, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $358.16, while the most cautious has a target of $260.64.

ASND operates in the Healthcare sector with a market capitalisation of $17B. The stock is up 19.4% year-to-date and is currently trading near the upper end of its 52-week range of $186.05 – $282.15.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

NBIX +31.6%
Neurocrine Biosciences, Inc.
$16B · P/E 23.7x · Buy
GMAB +25.5%
Genmab A/S
$19B · P/E 24.3x · Buy
ZBH +10.6%
Zimmer Biomet Holdings, Inc.
$19B · P/E 23.6x · Hold
JAZZ +13.4%
Jazz Pharmaceuticals plc
$16B · P/E 17.0x · Buy
MEDP -3.9%
Medpace Holdings, Inc.
$17B · P/E 35.5x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for ASND, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citigroup ● Initiated
Buy 2026-05-19 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-05-15 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-05-11 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-05-08 Building track record
B of A Securities - Reiterated
Buy → Buy 2026-04-16 Building track record
Wedbush reit
Outperform → Outperform 2026-04-09 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-03-03 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2026-02-12 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
71
out of 100
Coverage depth
22/30
Consensus clarity
22/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →